Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at NDORMS, University of Oxford and Warwick University have shown that intramedullary (IM) nail fixation following a fracture of the shinbone leads to faster recovery and lower costs.

Left: locking plate fixation. Right: IM nail fixation.

The Oxford Trauma team conducted a multicentre randomised clinical trial and compared over 300 patients treated with IM nail fixation versus locking plate fixation in the 12 months following a fracture of the distal tibia, also known as the shinbone.

Participants in the Fixation of Distal Tibia Fractures (FixDT) trial showed similar disability ratings at 6 and 12 months, but recovery was faster in the IM nail fixation group with significantly less disability at 3 months.

"Up until our trial, the best treatment for fractures of the distal tibia remained controversial. We are very pleased to be able to contribute an answer to the best form of treatment for these fractures and inform an evidence-based surgery approach in the NHS", says lead investigator Professor Matt Costa.

The team also looked at the cost-effectiveness of both treatments and concluded that IM nail fixation approach is cheaper.

Professor Costa comments: "The economic evaluation done as part of the trial strongly suggests IM nail fixation is the way to go on all accounts when it comes to fractures of the shinbone, so we hope this research can change NICE guidelines and have an impact not only for patients but for the NHS as a whole."

The tibia is the most commonly broken major bone in the leg and injuries usually require surgery, leading to prolonged periods away from work and social activities. Currently, the most common surgical treatment options are IM nail fixation, where a metal rod is inserted into the hollow center of the tibia, and locking plate fixation, where a plate is attached to the surface of the bone with fixed-angle screws.

This research has been published in JAMA, as well as made available as a full report by the NIHR Health Technology Assessment. A full cost analysis report has also been published in Bone and Joint.

Watch the FixDT video

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.